N/A
Completed N=4,748
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)
Source: ClinicalTrials.gov NCT00909389 ↗Enrolled (actual)
4,748
Serious AEs
0.1%
Results posted
Oct 2011
Primary outcomePrimary: Number of Participants Who Had an Adverse Event (AE). — 62 participants
Summary
This study aims to establish the safety, tolerability, and efficacy of Vytorin (R) (Ezetimibe + Simvastatin) (SCH 465981) on a select population of Filipinos with hypercholesterolemia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Had an Adverse Event (AE). |
62 | — |
Eligibility Criteria
Inclusion Criteria
- Outpatient men or women, age 18 years and above
- Patients with primary (heterozygous familial and non-familial) hypercholesterolemia
Exclusion Criteria
- Known hypersensitivity to Ezetimibe and Simvastatin
- Moderate to severe hepatic insufficiency
- Persistent elevation of serum transaminase levels of more than 1.5 times the upper limit of normal
- Pregnancy or lactation
- Concomitant intake of bile acid sequestrants (resins), nicotinic acid (niacin), fibric acid (fibrates), or cyclosporine
Data sourced from ClinicalTrials.gov (NCT00909389). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.